The results of the migraine study will be delayed from the previously reported schedule

Biohit Oyj Stock Exchange Release

07.09.2018 at 15:00 local time (EET)

The results of the migraine study will be delayed  from the autumn 2018 which was reported in Biohit’s Half Year Financial Report (H1 2018). In Estonia, unexpected problems have been encountered in finding eligible patients  for the study. Due to these challenges, the final results will not be available  until the first reporting period of 2019.

Additional information:

CEO Semi Korpela, Biohit Oyj

tel. +358 9 773 861

investor.relations@biohit.fi

www.biohithealthcare.com

Biohit Oyj in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission ‘Innovating for Health’ means that we provide innovative products and services to promote research and early diagnostics. Biohit is headquartered in Helsinki and has subsidiaries in Italy and the UK. Biohit’s B series shares (BIOBV) are quoted on NASDAQ OMX Helsinki under Small cap/Healthcare. www.biohithealthcare.com